Skip to main content

Advertisement

Log in

Telomerase promoter mutations in cancer: an emerging molecular biomarker?

  • Review and Perspectives
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

Cell immortalization has been considered for a long time as a classic hallmark of cancer cells. Besides telomerase reactivation, such immortalization could be due to telomere maintenance through the “alternative mechanism of telomere lengthening” (ALT) but the mechanisms underlying both forms of reactivation remained elusive. Mutations in the coding region of telomerase gene are very rare in the cancer setting, despite being associated with some degenerative diseases. Recently, mutations in telomerase (TERT) gene promoter were found in sporadic and familial melanoma and subsequently in several cancer models, notably in gliomas, thyroid cancer and bladder cancer. The importance of these findings has been reinforced by the association of TERT mutations in some cancer types with tumour aggressiveness and patient survival. In the first part of this review, we summarize the data on the biology of telomeres and telomerase, available methodological approaches and non-neoplastic diseases associated with telomere dysfunction. In the second part, we review the information on telomerase expression and genetic alterations in the most relevant types of cancer (skin, thyroid, bladder and central nervous system) on record, and discuss the value of telomerase as a new biomarker with impact on the prognosis and survival of the patients and as a putative therapeutic target.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, Marquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360–366. doi:10.1016/j.eururo.2013.08.052

    CAS  PubMed  Google Scholar 

  2. Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park JY, Rollison DE (2013) Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol 37:434–439. doi:10.1016/j.canep.2013.02.010

    PubMed  Google Scholar 

  3. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276. doi:10.1007/s00401-013-1141-6

    CAS  PubMed  Google Scholar 

  4. Aubert G, Lansdorp PM (2008) Telomeres and aging. Physiol Rev 88:557–579. doi:10.1152/physrev.00026.2007

    CAS  PubMed  Google Scholar 

  5. Baerlocher GM, Vulto I, de Jong G, Lansdorp PM (2006) Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc 1:2365–2376. doi:10.1038/nprot.2006.263

    CAS  PubMed  Google Scholar 

  6. Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, Laposa RR, Baehner FL, Sagebiel RW, Cleaver JE, Haqq C, Debs RJ, Blackburn EH, Kashani-Sabet M (2006) Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A 103:11306–11311. doi:10.1073/pnas.0510085103

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Baird DM, Rowson J, Wynford-Thomas D, Kipling D (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet 33:203–207. doi:10.1038/ng1084

    CAS  PubMed  Google Scholar 

  8. Bataille V, Kato BS, Falchi M, Gardner J, Kimura M, Lens M, Perks U, Valdes AM, Bennett DC, Aviv A, Spector TD (2007) Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 16:1499–1502. doi:10.1158/1055-9965.EPI-07-0152

    CAS  Google Scholar 

  9. Blackburn EH (1991) Structure and function of telomeres. Nature 350:569–573. doi:10.1038/350569a0

    CAS  PubMed  Google Scholar 

  10. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O’Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, Network TR (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. doi:10.1016/j.cell.2013.09.034

    CAS  PubMed  Google Scholar 

  11. Buckingham EM, Klingelhutz AJ (2011) The role of telomeres in the ageing of human skin. Exp Dermatol 20:297–302. doi:10.1111/j.1600-0625.2010.01242.x

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Burke LS, Hyland PL, Pfeiffer RM, Prescott J, Wheeler W, Mirabello L, Savage SA, Burdette L, Yeager M, Chanock S, De Vivo I, Tucker MA, Goldstein AM, Yang XR (2013) Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One 8:e71121. doi:10.1371/journal.pone.0071121

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Buseman CM, Wright WE, Shay JW (2012) Is telomerase a viable target in cancer? Mutat Res 730:90–97. doi:10.1016/j.mrfmmm.2011.07.006

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Cantara S, Pisu M, Frau DV, Caria P, Dettori T, Capezzone M, Capuano S, Vanni R, Pacini F (2012) Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. J Clin Endocrinol Metab 97:E1327–E1331. doi:10.1210/jc.2011-2096

    CAS  PubMed  Google Scholar 

  15. Capezzone M, Cantara S, Marchisotta S, Busonero G, Formichi C, Benigni M, Capuano S, Toti P, Pazaitou-Panayiotou K, Caruso G, Carli AF, Palummo N, Pacini F (2011) Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer. J Clin Endocrinol Metab 96:E1852–E1856. doi:10.1210/jc.2011-1003

    CAS  PubMed  Google Scholar 

  16. Capezzone M, Marchisotta S, Cantara S, Pacini F (2009) Telomeres and thyroid cancer. Curr Genom 10:526–533. doi:10.2174/138920209789503897

    CAS  Google Scholar 

  17. Carroll KA, Ly H (2009) Telomere dysfunction in human diseases: the long and short of it! Int J Clin Exp Pathol 2:528–543

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Carvalho L, Lipay M, Belfort F, Santos I, Andrade J, Haddad A, Brunstein F, Ferreira L (2006) Telomerase activity in prognostic histopathologic features of melanoma. J Plast Reconstr Aesthet Surg JPRAS 59:961–968. doi:10.1016/j.bjps.2006.01.022

    Google Scholar 

  19. Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, Wasserman JD, Elizabeth C, Alon N, Zhang L, Hovestadt V, Kool M, Jones DT, Zadeh G, Croul S, Hawkins C, Hitzler J, Wang JC, Baruchel S, Dirks PB, Malkin D, Pfister S, Taylor MD, Weksberg R, Tabori U (2013) Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 14:534–542. doi:10.1016/S1470-2045(13)70110-4

    CAS  PubMed  Google Scholar 

  20. Cawthon RM (2002) Telomere measurement by quantitative PCR. Nucleic Acids Res 30:e47

    PubMed Central  PubMed  Google Scholar 

  21. Cesare AJ, Reddel RR (2010) Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 11:319–330. doi:10.1038/nrg2763

    CAS  PubMed  Google Scholar 

  22. Cifuentes-Rojas C, Shippen DE (2012) Telomerase regulation. Mutat Res 730:20–27. doi:10.1016/j.mrfmmm.2011.10.003

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Cong YS, Wen J, Bacchetti S (1999) The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8:137–142

    CAS  PubMed  Google Scholar 

  24. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Muller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20:6958–6968. doi:10.1093/emboj/20.24.6958

    CAS  PubMed Central  PubMed  Google Scholar 

  25. Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, Maric I, Lanza F, Nasciuti F, Viaggi S, Gualco M, Bandelloni R, Truini M, Coviello DA, Zupo S, Mosci C, Pfeffer U (2014) Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer. doi:10.1038/bjc.2013.804

    PubMed  Google Scholar 

  26. Du HY, Pumbo E, Ivanovich J, An P, Maziarz RT, Reiss UM, Chirnomas D, Shimamura A, Vlachos A, Lipton JM, Goyal RK, Goldman F, Wilson DB, Mason PJ, Bessler M (2009) TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 113:309–316. doi:10.1182/blood-2008-07-166421

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Egberts F, Kruger S, Behrens HM, Bergner I, Papaspyrou G, Werner JA, Alkatout I, Haag J, Hauschild A, Rocken C (2014) Melanomas of unknown primary frequently harbor TERT-promoter mutations. Melanoma Res. doi:10.1097/CMR.0000000000000048

    PubMed  Google Scholar 

  28. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM (2005) Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105:1742–1749. doi:10.1182/blood-2003-12-4322

    CAS  PubMed  Google Scholar 

  29. Fabricius EVH, Raguse JR (2012) Molecular biology of basal cell carcinoma. In: Chapter 2, in Basal Cell Carcinoma, Madan, V (Ed.), published by InTech, Rijeka, Croatia, pp 19–54

  30. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N (2000) Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Investig Dermatol 114:259–267. doi:10.1046/j.1523-1747.2000.00870.x

    CAS  PubMed  Google Scholar 

  31. Garcia CK, Wright WE, Shay JW (2007) Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res 35:7406–7416. doi:10.1093/nar/gkm644

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W (1999) Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291:81–87

    CAS  PubMed  Google Scholar 

  33. Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL, Blasco MA (2001) Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 20:2619–2630. doi:10.1093/emboj/20.11.2619

    CAS  PubMed Central  PubMed  Google Scholar 

  34. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M (2013) High Incidence of activating tert promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. doi:10.1111/bpa.12110

    PubMed  Google Scholar 

  35. Gramatges MM, Bertuch AA (2013) Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Transl Res J Lab Clin Med 162:353–363. doi:10.1016/j.trsl.2013.05.003

    CAS  Google Scholar 

  36. Greider CW (1991) Telomerase is processive. Mol Cell Biol 11:4572–4580

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Griewank KG, Murali R, Schilling B, Schimming T, Moller I, Moll I, Schwamborn M, Sucker A, Zimmer L, Schadendorf D, Hillen U (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8:e80354. doi:10.1371/journal.pone.0080354

    PubMed Central  PubMed  Google Scholar 

  38. Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Susskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M (2013) TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 109:497–501. doi:10.1038/bjc.2013.312

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T (2013) TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol Off J U S Can Acad Pathol Inc. doi:10.1038/modpathol.2013.168

    Google Scholar 

  40. Gross TJ, Hunninghake GW (2001) Idiopathic pulmonary fibrosis. N Engl J Med 345:517–525. doi:10.1056/NEJMra003200

    CAS  PubMed  Google Scholar 

  41. Gunes C, Rudolph KL (2013) The role of telomeres in stem cells and cancer. Cell 152:390–393. doi:10.1016/j.cell.2013.01.010

    PubMed  Google Scholar 

  42. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, De Vivo I (2009) A prospective study of telomere length and the risk of skin cancer. J Investig Dermatol 129:415–421. doi:10.1038/jid.2008.238

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Harle-Bachor C, Boukamp P (1996) Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A 93:6476–6481

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585–621

    CAS  PubMed  Google Scholar 

  45. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425. doi:10.1126/science.1207313

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih Ie M, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, De Marzo AM, Terracciano L, Torbenson M, Meeker AK (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608–1615. doi:10.1016/j.ajpath.2011.06.018

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R (2014) Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 5:3401. doi:10.1038/ncomms4401

    PubMed  Google Scholar 

  48. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR (2005) A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res Off J Am Assoc Cancer Res 11:217–225

    CAS  Google Scholar 

  49. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N (1998) Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58:2117–2125

    CAS  PubMed  Google Scholar 

  50. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959–961. doi:10.1126/science.1230062

    CAS  PubMed  Google Scholar 

  51. Hreidarsson S, Kristjansson K, Johannesson G, Johannsson JH (1988) A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr Scand 77:773–775

    CAS  PubMed  Google Scholar 

  52. Hu S, Chan HL, Chen MC, Pang JH (2002) Telomerase expression in benign and malignant skin neoplasms: comparison of three major subunits. J Formos Med Assoc Taiwan Yi Zhi 101:593–597

    CAS  Google Scholar 

  53. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957–959. doi:10.1126/science.1229259

    CAS  PubMed  Google Scholar 

  54. Hurst CD, Platt FM, Knowles MA (2014) Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 65:367–369. doi:10.1016/j.eururo.2013.08.057

    CAS  PubMed  Google Scholar 

  55. Jendrzejewski J, Tomsic J, Lozanski G, Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT, Heerema NA, de la Chapelle A (2011) Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 96:E1876–E1880. doi:10.1210/jc.2011-1643

    CAS  PubMed Central  PubMed  Google Scholar 

  56. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722

    PubMed Central  PubMed  Google Scholar 

  57. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE, 2nd, Yan H, Bigner DD (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525

  58. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110:6021–6026. doi:10.1073/pnas.1303607110

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015

    CAS  PubMed  Google Scholar 

  60. Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A (2010) Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. Nat Protoc 5:1596–1607. doi:10.1038/nprot.2010.124

    CAS  PubMed  Google Scholar 

  61. Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73:7162–7167. doi:10.1158/0008-5472.CAN-13-2498

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, Wardelmann E, Schirmacher P, von Deimling A, Mechtersheimer G (2014) TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res CR 33:33. doi:10.1186/1756-9966-33-33

    Google Scholar 

  63. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915. doi:10.1007/s00401-013-1195-5

    CAS  PubMed  Google Scholar 

  64. Kulla E, Katz E (2008) Biosensor Techniques used for determination of telomerase activity in cancer cells. Sensors 8:347–369

    CAS  PubMed Central  Google Scholar 

  65. Kyo S, Takakura M, Fujiwara T, Inoue M (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99:1528–1538. doi:10.1111/j.1349-7006.2008.00878.x

    CAS  PubMed  Google Scholar 

  66. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562–E1566. doi:10.1210/jc.2013-2383

    CAS  PubMed  Google Scholar 

  67. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Shay JW (1995) Telomerase activity in human brain tumours. Lancet 346:1267–1268

    CAS  PubMed  Google Scholar 

  68. Liang G, Qureshi AA, Guo Q, De Vivo I, Han J (2011) No association between telomere length in peripheral blood leukocytes and the risk of nonmelanoma skin cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 20:1043–1045. doi:10.1158/1055-9965.EPI-11-0072

    CAS  Google Scholar 

  69. Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW (2014) TERT promoter mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol. doi:10.1111/cup.12323

    Google Scholar 

  70. Lin Y, Miyamoto H, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y (1996) Telomerase activity in human bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2:929–932

    CAS  Google Scholar 

  71. Lindsey JC, Schwalbe EC, Potluri S, Bailey S, Williamson D, Clifford SC (2014) TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Acta Neuropathol 127:307–309. doi:10.1007/s00401-013-1225-3

    PubMed  Google Scholar 

  72. Liu JP, Chen W, Schwarer AP, Li H (2010) Telomerase in cancer immunotherapy. Biochim Biophys Acta 1805:35–42. doi:10.1016/j.bbcan.2009.09.001

    CAS  PubMed  Google Scholar 

  73. Liu T, Liang X, Bjorkholm M, Jia J, Xu D (2014) The absence of TERT promoter mutations in primary gastric cancer. Gene 540:266–267. doi:10.1016/j.gene.2014.02.051

    CAS  PubMed  Google Scholar 

  74. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D (2013) The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. doi:10.1038/onc.2013.446

    Google Scholar 

  75. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:603–610. doi:10.1530/ERC-13-0210

    PubMed Central  PubMed  Google Scholar 

  76. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M (2014) TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. doi:10.1210/jc.2013-4048

    Google Scholar 

  77. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M (2013) Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12:1637–1638. doi:10.4161/cc.24662

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S (2013) Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro-Oncology 15:423–432. doi:10.1093/neuonc/nos329

    PubMed Central  PubMed  Google Scholar 

  79. Marrone A, Walne A, Dokal I (2005) Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr Opin Genet Dev 15:249–257. doi:10.1016/j.gde.2005.04.004

    CAS  PubMed  Google Scholar 

  80. Melo M, Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C, Castro P, Prazeres H, Lima J, Amaro T, Lobo C, Martins MJ, Moura M, Cavaco B, Leite V, Cameselle-Teijeiro JM, Carrilho F, Cavalheiro M, Maximo V, Sobrinho-Simoes M, Soares P (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. doi:10.1210/jc.2013-3734

    Google Scholar 

  81. Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, Luzi P (2000) Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum Pathol 31:1018–1021. doi:10.1053/hupa.2000.9779

    CAS  PubMed  Google Scholar 

  82. Mocellin S, Pooley KA, Nitti D (2013) Telomerase and the search for the end of cancer. Trends Mol Med 19:125–133. doi:10.1016/j.molmed.2012.11.006

    CAS  PubMed  Google Scholar 

  83. Montanaro L, Calienni M, Ceccarelli C, Santini D, Taffurelli M, Pileri S, Trere D, Derenzini M (2008) Relationship between dyskerin expression and telomerase activity in human breast cancer. Cell Oncol Off J Int Soc Cell Oncol 30:483–490

    CAS  Google Scholar 

  84. Morii A, Komiya A, Okumura A, Fuse H (2010) Telomerase activity in bladder cancer tissue. Exp Ther Med 1:85–88. doi:10.3892/etm_00000015

    PubMed Central  PubMed  Google Scholar 

  85. Murnane JP (2012) Telomere dysfunction and chromosome instability. Mutat Res 730:28–36. doi:10.1016/j.mrfmmm.2011.04.008

    CAS  PubMed Central  PubMed  Google Scholar 

  86. Nan H, Du M, De Vivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, Qureshi AA, Hunter DJ, Han J (2011) Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 71:6758–6763. doi:10.1158/0008-5472.CAN-11-1988

    CAS  PubMed Central  PubMed  Google Scholar 

  87. Nandakumar J, Cech TR (2013) Finding the end: recruitment of telomerase to telomeres. Nat Rev Mol Cell Biol 14:69–82. doi:10.1038/nrm3505

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218. doi:10.1038/ncomms3218

    PubMed Central  PubMed  Google Scholar 

  89. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937. doi:10.1007/s00401-013-1163-0

    CAS  PubMed  Google Scholar 

  90. Okumura A, Mizuno I, Nagakawa O, Fuse H (2004) Telomerase activity is correlated with lower grade and lower stage bladder carcinomas. Int J Urol Off J Japan Urol Assoc 11:1082–1086. doi:10.1111/j.1442-2042.2004.00960.x

    CAS  Google Scholar 

  91. Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, Newbold RF (1999) Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer 79:47–53. doi:10.1038/sj.bjc.6690010

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277:15566–15572. doi:10.1074/jbc.M201266200

    CAS  PubMed  Google Scholar 

  93. Perrem K, Lynch A, Al Nooh F, Leader M, Elaine K (2008) The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population. Hum Pathol 39:1034–1041. doi:10.1016/j.humpath.2007.11.008

    CAS  PubMed  Google Scholar 

  94. Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimaraes I, Manuel Lopes J, Sobrinho-Simoes M, Soares P (2014) TERT Promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Investig Dermatol. doi:10.1038/jid.2014.163

    PubMed  Google Scholar 

  95. Preto A, Cameselle-Teijeiro J, Moldes-Boullosa J, Soares P, Cameselle-Teijeiro JF, Silva P, Reis-Filho JS, Reyes-Santias RM, Alfonsin-Barreiro N, Forteza J, Sobrinho-Simoes M (2004) Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Mod Pathol Off J U S Can Acad Pathol Inc 17:819–826. doi:10.1038/modpathol.3800124

    CAS  Google Scholar 

  96. Prud’homme GJ (2005) DNA vaccination against tumors. J Gene Med 7:3–17. doi:10.1002/jgm.669

    PubMed  Google Scholar 

  97. Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, Shi B, Hou P (2014) TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer. doi:10.1002/ijc.28728

    Google Scholar 

  98. Qu Y, Shi L, Wang D, Zhang B, Yang Q, Ji M, Shi B, Hou P (2013) Low frequency of TERT promoter mutations in a large cohort of gallbladder and gastric cancers. Int J Cancer. doi:10.1002/ijc.28633

    Google Scholar 

  99. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund NP, Steineck G, Schadendorf D, Hemminki K, Kumar R (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A 110:17426–17431. doi:10.1073/pnas.1310522110

    CAS  PubMed Central  PubMed  Google Scholar 

  100. Ramirez RD, D’Atri S, Pagani E, Faraggiana T, Lacal PM, Taylor RS, Shay JW (1999) Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. Neoplasia 1:42–49

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Reis-Filho JS, Preto A, Soares P, Ricardo S, Cameselle-Teijeiro J, Sobrinho-Simoes M (2003) p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Mod Pathol Off J U S Can Acad Pathol Inc 16:43–48. doi:10.1097/01.MP.0000047306.72278.39

    Google Scholar 

  102. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, Jung S, Saad AG, Liau LM, Albrecht S, Zollo M, Cooper MK, Thompson RC, Delattre OO, Bourdeaut F, Doz FF, Garami M, Hauser P, Carlotti CG, Van Meter TE, Massimi L, Fults D, Pomeroy SL, Kumabe T, Ra YS, Leonard JR, Elbabaa SK, Mora J, Rubin JB, Cho YJ, McLendon RE, Bigner DD, Eberhart CG, Fouladi M, Wechsler-Reya RJ, Faria CC, Croul SE, Huang A, Bouffet E, Hawkins CE, Dirks PB, Weiss WA, Schuller U, Pollack IF, Rutkowski S, Meyronet D, Jouvet A, Fevre-Montange M, Jabado N, Perek-Polnik M, Grajkowska WA, Kim SK, Rutka JT, Malkin D, Tabori U, Pfister SM, Korshunov A, von Deimling A, Taylor MD (2013) TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 126:917–929. doi:10.1007/s00401-013-1198-2

    CAS  PubMed Central  PubMed  Google Scholar 

  103. Ruden M, Puri N (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39:444–456. doi:10.1016/j.ctrv.2012.06.007

    CAS  PubMed  Google Scholar 

  104. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, Majewski S, Krupp G, Jablonska S, Parwaresch R (2000) Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am J Pathol 156:1425–1432. doi:10.1016/S0002-9440(10)65011-0

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Saleh S, King-Yin Lam A, Gertraud Buettner P, Glasby M, Raasch B, Ho YH (2007) Telomerase activity of basal cell carcinoma in patients living in North Queensland, Australia. Hum Pathol 38:1023–1029. doi:10.1016/j.humpath.2006.12.006

    CAS  PubMed  Google Scholar 

  106. Sano T, Asai A, Mishima K, Fujimaki T, Kirino T (1998) Telomerase activity in 144 brain tumours. Br J Cancer 77:1633–1637

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Savage SA, Bertuch AA (2010) The genetics and clinical manifestations of telomere biology disorders. Genet Med Off J Am Coll Med Genet 12:753–764. doi:10.1097/GIM.0b013e3181f415b5

    Google Scholar 

  108. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP (2008) TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 82:501–509. doi:10.1016/j.ajhg.2007.10.004

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Scheinberg P, Young NS (2012) How I treat acquired aplastic anemia. Blood 120:1185–1196. doi:10.1182/blood-2011-12-274019

    CAS  PubMed Central  PubMed  Google Scholar 

  110. Scott GA, Laughlin TS, Rothberg PG (2013) Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol Off J U S Can Acad Pathol Inc. doi:10.1038/modpathol.2013.167

    Google Scholar 

  111. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791. doi:10.1016/S0959-8049(97)00062-2

    CAS  PubMed  Google Scholar 

  112. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idbaih A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lonn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau C, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41:899–904. doi:10.1038/ng.407

    CAS  PubMed  Google Scholar 

  113. Skvortsov DA, Zvereva ME, Shpanchenko OV, Dontsova OA (2011) Assays for detection of telomerase activity. Acta Nat 3:48–68

    CAS  Google Scholar 

  114. Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Maximo V, Sobrinho-Simoes M (2011) Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genom 12:609–617. doi:10.2174/138920211798120853

    CAS  Google Scholar 

  115. Svenson U, Roos G (2009) Telomere length as a biological marker in malignancy. Biochim Biophys Acta 1792:317–323. doi:10.1016/j.bbadis.2009.01.017

    CAS  PubMed  Google Scholar 

  116. Szostak JW, Blackburn EH (1982) Cloning yeast telomeres on linear plasmid vectors. Cell 29:245–255

    CAS  PubMed  Google Scholar 

  117. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Salle F, Cazes A, Copin MC, Hofman P, Andujar P, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D (2013) Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene. doi:10.1038/onc.2013.351

    PubMed  Google Scholar 

  118. Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA, Shay JW (1996) Detection of telomerase activity in malignant and nonmalignant skin conditions. J Investig Dermatol 106:759–765

    CAS  PubMed  Google Scholar 

  119. Ueda M, Ouhtit A, Bito T, Nakazawa K, Lubbe J, Ichihashi M, Yamasaki H, Nakazawa H (1997) Evidence for UV-associated activation of telomerase in human skin. Cancer Res 57:370–374

    CAS  PubMed  Google Scholar 

  120. van Nistelrooij AM, Zwarthoff EC, Post E, Lurkin I, van Marion R, Kopershoek E, Biermann K, Wijnhoven BP, Dinjens WN (2013) Absence of TERT promoter mutations in esophageal adenocarcinoma. Int J Cancer. doi:10.1002/ijc.28527

    Google Scholar 

  121. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185. doi:10.1038/ncomms3185

    PubMed  Google Scholar 

  122. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, Anderson KS, Hahn WC, Nadler LM (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res Off J Am Assoc Cancer Res 10:828–839

    CAS  Google Scholar 

  123. Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H, Yan K, Hu S, Bjorkholm M, Fan Y, Xu D (2014) TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget 5:1829–1836

  124. Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih Ie M, Wang TL (2014) Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 232:473–481. doi:10.1002/path.4315

    CAS  PubMed  Google Scholar 

  125. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, Chen C, Lv Z, Tang A, Sun X, Lu J, Li W, Zhou J, Gui Y, Zhou F, Wang D, Cai Z (2014) Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 65:274–277. doi:10.1016/j.eururo.2013.10.038

    CAS  PubMed  Google Scholar 

  126. Yang CH, Hung WC, Wang SL, Kang WY, Chen WT, Huang YC, Su YC, Chai CY (2008) Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma. APMIS Acta Pathol Microbiol Immunol Scand 116:309–316. doi:10.1111/j.1600-0463.2008.00905.x

    Google Scholar 

  127. Zhao Y, Chen G, Zhao Y, Song X, Chen H, Mao Y, Lu D (2012) Fine-mapping of a region of chromosome 5p15.33 (TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L haplotype are associated with glioma susceptibility in a Chinese population. Int J Cancer 131:1569–1576. doi:10.1002/ijc.27417

    CAS  PubMed  Google Scholar 

  128. Zhao Y, Gao Y, Chen Z, Hu X, Zhou F, He J (2013) Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int J Cancer. doi:10.1002/ijc.28360

    PubMed Central  Google Scholar 

  129. Zhou X, Xing D (2012) Assays for human telomerase activity: progress and prospects. Chem Soc Rev 41:4643–4656. doi:10.1039/c2cs35045a

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paula Soares.

Additional information

João Vinagre, Vasco Pinto and Ricardo Celestino contributed equally to the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vinagre, J., Pinto, V., Celestino, R. et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker?. Virchows Arch 465, 119–133 (2014). https://doi.org/10.1007/s00428-014-1608-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1608-4

Keywords

Navigation